Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 1/20 | 0.43 |
| ▸ | CCR2 | P41597 | 4/20 | 0.41 |
| ▸ | TACR1 | P25103 | 4/20 | 0.40 |
| ▸ | MTTP | P55157 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.38 |
| ▸ | CCR1 | P32246 | 1/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 4/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6411908 | 0.91 | KCNA5 (0.43) | KCNA5CCR2TACR1KCNH2SCN9A | |
| SCHEMBL6411734 | 0.83 | CCR2 (0.41) | CCR2TACR1KCNH2SCN9ASCN5A | |
| SCHEMBL6418317 | 0.81 | MAPK1 (0.45) | TACR1HSD17B10TSHRNPSR1 | |
| SCHEMBL6418322 | 0.79 | HSD17B10 (0.55) | KCNA5TACR1KCNH2SCN9ASCN5A | |
| SCHEMBL6416211 | 0.77 | KMT2A (0.42) | KCNA5CCR2KCNH2SCN9ASCN5A | |
| SCHEMBL6413158 | 0.76 | SCN9A (0.41) | CCR2TACR1KCNH2SCN9ASCN5A | |
| SCHEMBL6417894 | 0.75 | UBE2M (0.46) | TACR1 | |
| SCHEMBL6417356 | 0.74 | DRD2 (0.46) | CCR2TACR1 | |
| SCHEMBL6418274 | 0.74 | MAPK1 (0.51) | HSD17B10TSHRNPSR1 | |
| SCHEMBL6411904 | 0.73 | SCN9A (0.41) | CCR2TACR1KCNH2SCN9ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050124614-A1 | 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis | AXYS PHARMACEUTICALS, INC. (US) | 2005-06-09 | — | — | US | claimed |
| WO-2004004727-A1 | 3,4-DIHYDROISOQUINOLIN-1-ONE DERIVATIVES AS INDUCERS OF APOPTOSIS | AXYS PHARMACEUTICALS, INC. (US) | 2004-01-15 | — | — | WO | claimed |
| US-20050124614-A1 | 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis | AXYS PHARMACEUTICALS, INC. (US) | 2005-06-09 | — | — | US | disclosed |
| WO-2004004727-A1 | 3,4-DIHYDROISOQUINOLIN-1-ONE DERIVATIVES AS INDUCERS OF APOPTOSIS | AXYS PHARMACEUTICALS, INC. (US) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124614-A1 | 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis | CASP3, BAX, BAD | KCNA5 4622/4885CCR2 2916/4885TACR1 4639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.